Harold E. Barry Selick

Dr. Selick has served on our board of directors since February 2009. Dr. Selick is Vice Chancellor for Business Development, Innovation and Partnerships at University of California San Francisco. He also serves as Chairman of Molecular Templates effective August 2017. He served as CEO of Threshold Pharmaceuticals from June 2002 to April 2017, which recently merged with Molecular Templates. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL), he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab). Dr. Selick serves as Lead Director of PDL, a public company, and serves as Chairman of the board of directors of Catalyst Biosciences, a privately held drug discovery and development company. Dr. Selick received his B.A. in Biophysics and Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.